JP4177455B2 - 逆キメラおよびハイブリッドオリゴヌクレオチド - Google Patents

逆キメラおよびハイブリッドオリゴヌクレオチド Download PDF

Info

Publication number: JP4177455B2
Authority: JP; Japan
Prior art keywords: oligonucleotides; oligonucleotide; hybrid; phosphorothioate; reverse
Prior art date: 1995-08-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP50953597A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11512088A5 (2

JPH11512088A (ja

Inventor

アグラワル，サドヒル

Original Assignee

イデラ・ファーマシューティカルズ・インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-17

Filing date

1996-08-16

Publication date

2008-11-05

1996-08-16 Application filed by イデラ・ファーマシューティカルズ・インコーポレイテッド filed Critical イデラ・ファーマシューティカルズ・インコーポレイテッド

1999-10-19 Publication of JPH11512088A publication Critical patent/JPH11512088A/ja

2004-08-12 Publication of JPH11512088A5 publication Critical patent/JPH11512088A5/ja

2008-11-05 Application granted granted Critical

2008-11-05 Publication of JP4177455B2 publication Critical patent/JP4177455B2/ja

2016-08-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 192
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract description 97
230000002441 reversible effect Effects 0.000 title description 73
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims abstract description 54
230000014509 gene expression Effects 0.000 claims abstract description 48
230000000694 effects Effects 0.000 claims abstract description 35
230000002829 reductive effect Effects 0.000 claims abstract description 12
108090000623 proteins and genes Proteins 0.000 claims description 33
230000000295 complement effect Effects 0.000 claims description 25
239000002773 nucleotide Substances 0.000 claims description 18
125000003729 nucleotide group Chemical group 0.000 claims description 17
108091028664 Ribonucleotide Proteins 0.000 claims description 16
239000002336 ribonucleotide Substances 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
125000002652 ribonucleotide group Chemical class 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 8
229940124276 oligodeoxyribonucleotide Drugs 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 2
239000005547 deoxyribonucleotide Substances 0.000 claims description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 4
125000001805 pentosyl group Chemical group 0.000 claims 2
238000006467 substitution reaction Methods 0.000 claims 2
230000005856 abnormality Effects 0.000 claims 1
230000002490 cerebral effect Effects 0.000 claims 1
230000014493 regulation of gene expression Effects 0.000 claims 1
230000000692 anti-sense effect Effects 0.000 abstract description 10
230000001225 therapeutic effect Effects 0.000 abstract description 7
239000000203 mixture Substances 0.000 description 23
210000004027 cell Anatomy 0.000 description 18
239000002777 nucleoside Substances 0.000 description 16
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
238000000034 method Methods 0.000 description 14
125000003835 nucleoside group Chemical class 0.000 description 13
238000002474 experimental method Methods 0.000 description 12
150000004713 phosphodiesters Chemical class 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
102100034343 Integrase Human genes 0.000 description 11
101710203526 Integrase Proteins 0.000 description 11
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 10
238000012360 testing method Methods 0.000 description 10
239000000074 antisense oligonucleotide Substances 0.000 description 9
238000012230 antisense oligonucleotides Methods 0.000 description 9
108020000948 Antisense Oligonucleotides Proteins 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
230000035602 clotting Effects 0.000 description 8
230000024203 complement activation Effects 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
238000001802 infusion Methods 0.000 description 6
230000002297 mitogenic effect Effects 0.000 description 6
230000009467 reduction Effects 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 5
241000700605 Viruses Species 0.000 description 5
-1 alkyl phosphate Chemical compound 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
108700028369 Alleles Proteins 0.000 description 4
241000714474 Rous sarcoma virus Species 0.000 description 4
108090000190 Thrombin Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
241000712461 unidentified influenza virus Species 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000000178 monomer Substances 0.000 description 3
239000002342 ribonucleoside Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
230000005679 Peltier effect Effects 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
241000242678 Schistosoma Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
125000005600 alkyl phosphonate group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000004019 antithrombin Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
244000045947 parasite Species 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000012827 research and development Methods 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000009452 underexpressoin Effects 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
241000393496 Electra Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
108010006464 Hemolysin Proteins Proteins 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
101000685724 Homo sapiens Protein S100-A4 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102000016397 Methyltransferase Human genes 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000047703 Nonion Species 0.000 description 1
239000007990 PIPES buffer Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
241000223960 Plasmodium falciparum Species 0.000 description 1
241001505293 Plasmodium ovale Species 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
102100023087 Protein S100-A4 Human genes 0.000 description 1
108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
108060003196 globin Proteins 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003228 hemolysin Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
230000008722 morphological abnormality Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011022 operating instruction Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000002972 pentoses Chemical group 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Virology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

JP50953597A 1995-08-17 1996-08-16 逆キメラおよびハイブリッドオリゴヌクレオチド Expired - Lifetime JP4177455B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/516,454		1995-08-17
US08/516,454 US5652356A (en)	1995-08-17	1995-08-17	Inverted chimeric and hybrid oligonucleotides
PCT/US1996/013371 WO1997006662A2 (en)	1995-08-17	1996-08-16	Inverted chimeric and hybrid oligonucleotides

Publications (3)

Publication Number	Publication Date
JPH11512088A JPH11512088A (ja)	1999-10-19
JPH11512088A5 JPH11512088A5 (2)	2004-08-12
JP4177455B2 true JP4177455B2 (ja)	2008-11-05

Family

ID=24055671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50953597A Expired - Lifetime JP4177455B2 (ja)	1995-08-17	1996-08-16	逆キメラおよびハイブリッドオリゴヌクレオチド

Country Status (11)

Country	Link
US (3)	US5652356A (2)
EP (2)	EP1340765B1 (2)
JP (1)	JP4177455B2 (2)
AT (2)	ATE411333T1 (2)
AU (1)	AU6953896A (2)
CA (1)	CA2229811C (2)
DE (2)	DE69628864T2 (2)
DK (1)	DK1019428T3 (2)
ES (2)	ES2315442T3 (2)
PT (1)	PT1019428E (2)
WO (1)	WO1997006662A2 (2)

Families Citing this family (456)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US6346614B1 (en) *	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
IL107150A0 (en) *	1992-09-29	1993-12-28	Isis Pharmaceuticals Inc	Oligonucleotides having a conserved g4 core sequence
AU679566B2 (en)	1993-09-03	1997-07-03	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en) *	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5989912A (en) *	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
US5849902A (en) *	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
US20020165174A1 (en) *	1997-01-31	2002-11-07	Gill Parkash S.	Methods and compositions for antisense VEGF oligonucleotides
US6291667B1 (en)	1997-01-31	2001-09-18	Parkash S. Gill	Method and composition for treatment of kaposi's sarcoma
US6716625B1 (en)	1997-04-16	2004-04-06	Claude Selitrennikoff	Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US6489304B2 (en) *	1997-05-01	2002-12-03	Hybridon, Inc.	Hyperstructure-forming carriers
DE69834038D1 (de)	1997-07-01	2006-05-18	Isis Pharmaceutical Inc	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
WO1999009154A2 (en) *	1997-08-19	1999-02-25	Hybridon, Inc.	Novel hiv-specific synthetic oligonucleotides and methods of their use
US6013786A (en) *	1997-08-22	2000-01-11	Hybridon, Inc.	MDM2-specific antisense oligonucleotides
US6306831B1 (en)	1997-09-12	2001-10-23	Qik Technologies, Inc.	Transplacental delivery of oligonucleotides
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6127535A (en)	1997-11-05	2000-10-03	Ribozyme Pharmaceuticals, Inc.	Nucleoside triphosphates and their incorporation into oligonucleotides
AU3465599A (en) *	1998-04-01	1999-10-18	Hybridon, Inc.	Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
AU3751299A (en)	1998-04-20	1999-11-08	Ribozyme Pharmaceuticals, Inc.	Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
JP2002515514A (ja)	1998-05-21	2002-05-28	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの局所送逹のための組成物及び方法
EP1080103A4 (en)	1998-05-21	2003-07-02	Isis Pharmaceuticals Inc	PREPARATIONS AND METHOD FOR THE NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
JP2003523166A (ja)	1998-09-29	2003-08-05	ガミダセルリミテッド	幹細胞および前駆細胞の増殖と分化を制御する方法
US6127124A (en)	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US20030220486A1 (en) *	1999-04-01	2003-11-27	Wen-Qiang Zhou	Mixed backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
DK1200580T3 (da) *	1999-08-13	2005-04-11	Hybridon Inc	Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
US6677445B1 (en)	1999-08-27	2004-01-13	Chiron Corporation	Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US20020082227A1 (en) *	1999-09-30	2002-06-27	Scott Henry	Use of oligonucleotides for inhibition of complement activation
US7332275B2 (en)	1999-10-13	2008-02-19	Sequenom, Inc.	Methods for detecting methylated nucleotides
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
EP2093292A2 (en)	2000-03-24	2009-08-26	Methylgene, Inc.	Inhibition of specific histone deacetylase isoforms
WO2001074346A2 (en) *	2000-04-03	2001-10-11	Hybridon, Inc.	Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US7846733B2 (en) *	2000-06-26	2010-12-07	Nugen Technologies, Inc.	Methods and compositions for transcription-based nucleic acid amplification
US6958214B2 (en)	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8153121B2 (en)	2000-10-06	2012-04-10	Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center	Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
US8178304B2 (en) *	2000-10-06	2012-05-15	Smith Terry J	Diagnostic methods relating to Graves' disease and other autoimmune disorders
WO2002048402A2 (en)	2000-12-13	2002-06-20	Nugen Technologies, Inc.	Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof
US20030148970A1 (en) *	2001-01-12	2003-08-07	Besterman Jeffrey M.	Methods for specifically inhibiting histone deacetylase-4
US20030152557A1 (en) *	2001-01-12	2003-08-14	Besterman Jeffrey M.	Methods for inhibiting histone deacetylase-4
JP4542312B2 (ja)	2001-03-09	2010-09-15	ニューゲンテクノロジーズ，インコーポレイテッド	Ｒｎａ配列の増幅のための方法および組成物
WO2002072773A2 (en) *	2001-03-09	2002-09-19	Nugen Technologies, Inc.	Methods and compositions for amplification of rna sequences
US20030083292A1 (en) *	2001-05-11	2003-05-01	Macleod Alan Robert	Inhibitors of DNA methyltransferase isoforms
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2790034A1 (en)	2001-06-21	2003-01-03	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US20040266718A1 (en) *	2001-08-06	2004-12-30	Zuomei Li	Inhibition of specific histone deacetylase isoforms
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US20030096781A1 (en) *	2001-08-31	2003-05-22	University Of Southern California	IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
EP1487877B1 (en)	2001-09-18	2010-10-27	Genentech, Inc.	Compositions and methods for the diagnosis of tumors
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003088808A2 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
AU2002364945A1 (en) *	2001-10-25	2003-07-09	Neurogenetics, Inc.	Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030224380A1 (en) *	2001-10-25	2003-12-04	The General Hospital Corporation	Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) *	2001-10-25	2003-09-11	Neurogenetics, Inc.	Genetic markers for Alzheimer's disease and methods using the same
ITMI20012367A1 (it) *	2001-11-09	2003-05-09	Visufarma S R L	Oligonucleotidi antisenso che regolano l'espressione del gene antiapoptotico bcl-2
US20040091893A1 (en) *	2001-11-27	2004-05-13	Jeffrey Gordon	Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
JP2005518195A (ja) *	2001-11-27	2005-06-23	ワシントン・ユニバーシティ	治療用タンパク質および治療方法
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en)	2002-01-25	2006-06-07	Gamida Cell Ltd	PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
WO2003078567A2 (en) *	2002-03-18	2003-09-25	Gamida-Cell Ltd.	Methods of inducing differentiation in ex vivo expanded stem cells
AU2003228809A1 (en)	2002-05-03	2003-11-17	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20030220844A1 (en) *	2002-05-24	2003-11-27	Marnellos Georgios E.	Method and system for purchasing genetic data
WO2003106617A2 (en) *	2002-06-12	2003-12-24	Tel Aviv Medical Center Research Development Fund	Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
US20040072770A1 (en) *	2002-07-03	2004-04-15	Besterman Jeffrey M.	Methods for specifically inhibiting histone deacetylase-7 and 8
US7229976B2 (en)	2002-09-26	2007-06-12	Isis Pharmaceuticals, Inc.	Modulation of forkhead box O1A expression
EP1552025A4 (en) *	2002-10-18	2006-12-13	Cylene Pharmaceuticals Inc	METHOD FOR IDENTIFYING ANTIVIRAL MOLECULES DETECTED BY A QUADRUPLEX STRUCTURE
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003287505A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
EP2336318B1 (en)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense modulation of apolipoprotein b expression
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
CA2506127C (en)	2002-11-15	2013-07-09	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
EP2112229A3 (en)	2002-11-25	2009-12-02	Sequenom, Inc.	Methods for identifying risk of breast cancer and treatments thereof
US7371840B2 (en)	2003-01-08	2008-05-13	The University Of Southern California	Isolation and characterization of ECA1, a gene overexpressed in endometrioid carcinomas of ovary and endometrium
WO2004072284A1 (en)	2003-02-11	2004-08-26	Antisense Therapeutics Ltd	Modulation of insulin like growth factor i receptor expression
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US20040198640A1 (en) *	2003-04-02	2004-10-07	Dharmacon, Inc.	Stabilized polynucleotides for use in RNA interference
JP2006523465A (ja)	2003-04-14	2006-10-19	ニューゲンテクノロジーズ，インコーポレイテッド	ランダムにプライミングされる複合プライマーを用いる大規模増幅
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
EP1644475A4 (en) *	2003-06-20	2009-06-03	Isis Pharmaceuticals Inc	DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050095627A1 (en) *	2003-09-03	2005-05-05	The Salk Institute For Biological Studies	Multiple antigen detection assays and reagents
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
KR100750788B1 (ko)	2003-09-18	2007-08-20	아이시스 파마수티컬즈 인코포레이티드	ｅＩＦ4Ｅ 발현의 조정
WO2005027962A1 (en)	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
ES2437491T3 (es)	2003-10-10	2014-01-10	Alchemia Oncology Pty Limited	Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
US20050120397A1 (en) *	2003-11-24	2005-06-02	Hermann Steller	Compounds and methods for regulation of spermatid differentiation
US7741070B2 (en) *	2003-12-24	2010-06-22	Massachusetts Institute Of Technology	Gene targets for enhanced carotenoid production
US7695932B2 (en) *	2003-12-24	2010-04-13	Massachusetts Institute Of Technology	Gene targets for enhanced carotenoid production
US7608699B2 (en) *	2003-12-29	2009-10-27	Rockefeller University	Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
US20050164271A1 (en)	2004-01-20	2005-07-28	Sanjay Bhanot	Modulation of glucocorticoid receptor expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
EP2123759B1 (en) *	2004-02-06	2014-01-15	Thermo Fisher Scientific Biosciences Inc.	Stabilized RNAS as transfection controls and silencing reagents
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en)	2004-03-15	2005-09-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of rna by rnase h
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005097817A2 (en)	2004-04-05	2005-10-20	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
AU2005252663B2 (en) *	2004-06-03	2011-07-07	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US8680062B2 (en)	2004-07-06	2014-03-25	Deliversir Ltd.	System for delivering therapeutic agents into living cells and cells nuclei
PL1786472T3 (pl)	2004-08-10	2013-06-28	Kastle Therapeutics Llc	Antysensowna modulacja ekspresji apolipoproteiny B
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
EP1799812A4 (en)	2004-09-16	2009-09-09	Gamida Cell Ltd	EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
EP2397563A3 (en)	2004-09-17	2012-07-18	Isis Pharmaceuticals, Inc.	Enhanced antisense oligonucleotides
AU2005327506B2 (en)	2004-10-20	2010-07-08	Antisense Therapeutics Ltd	Antisense modulation of integrin alpha4 expression
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US20060166234A1 (en) *	2004-11-22	2006-07-27	Barbara Robertson	Apparatus and system having dry control gene silencing compositions
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
WO2006086345A2 (en) *	2005-02-07	2006-08-17	The Trustees Of Columbia University In The City Of New York	Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
EP1869076A2 (en)	2005-03-10	2007-12-26	Genentech, Inc.	Methods and compositions for modulating vascular integrity
EP1879626A4 (en)	2005-04-19	2011-03-23	Massachusetts Inst Technology	AMPHIPHILIC POLYMERS AND METHOD FOR USE THEREOF
EP1891141B1 (en)	2005-05-31	2016-11-16	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007030759A2 (en) *	2005-09-07	2007-03-15	Nugen Technologies, Inc.	Improved nucleic acid amplification procedure
WO2007031877A2 (en) *	2005-09-16	2007-03-22	Coley Pharmaceutical Gmbh	Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
US20090291437A1 (en) *	2005-11-02	2009-11-26	O'brien Sean	Methods for targeting quadruplex sequences
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
US8288354B2 (en)	2005-12-28	2012-10-16	The Scripps Research Institute	Natural antisense and non-coding RNA transcripts as drug targets
PT2161038E (pt)	2006-01-26	2014-03-10	Isis Pharmaceuticals Inc	Composições e suas utilizações dirigidas à huntingtina
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
EP1984499B1 (en)	2006-01-27	2015-05-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
JP5342881B2 (ja)	2006-01-27	2013-11-13	アイシスファーマシューティカルズ，インコーポレーテッド	６−修飾された二環式核酸類似体
EP2023940B1 (en)	2006-05-05	2011-06-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of sglt2
AU2007249349B2 (en) *	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
US20100196336A1 (en)	2006-05-23	2010-08-05	Dongsu Park	Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
WO2008036841A2 (en)	2006-09-22	2008-03-27	Dharmacon, Inc.	Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
EP1935428A1 (en) *	2006-12-22	2008-06-25	Antisense Pharma GmbH	Oligonucleotide-polymer conjugates
US8507200B2 (en)	2007-02-09	2013-08-13	Northwestern University	Particles for detecting intracellular targets
US9156865B2 (en)	2007-04-23	2015-10-13	Deliversir Ltd	System for delivering therapeutic agents into living cells and cells nuclei
PT2144633E (pt) *	2007-04-23	2014-10-27	Deliversir Ltd	Um sistema para a administração de agentes terapêuticos em células vivas e núcleos de células
US9556210B2 (en)	2007-04-23	2017-01-31	Sabag-Rfa Ltd.	System for delivering therapeutic agents into living cells and cells nuclei
EP2170917B1 (en)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2160464T3 (da)	2007-05-30	2014-08-04	Univ Northwestern	Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
EP2173760B2 (en)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
US8097422B2 (en)	2007-06-20	2012-01-17	Salk Institute For Biological Studies	Kir channel modulators
CA2692579C (en) *	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
WO2009023855A2 (en)	2007-08-15	2009-02-19	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US7951785B2 (en)	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
US20100280098A1 (en) *	2007-10-05	2010-11-04	Juliano Rudolph L	Receptor targeted oligonucleotides
WO2009064920A2 (en)	2007-11-13	2009-05-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating protein expression
US8916531B2 (en)	2007-11-20	2014-12-23	Isis Pharmaceuticals, Inc.	Modulation of CD40 expression
US8546556B2 (en) *	2007-11-21	2013-10-01	Isis Pharmaceuticals, Inc	Carbocyclic alpha-L-bicyclic nucleic acid analogs
US7845686B2 (en) *	2007-12-17	2010-12-07	S & B Technical Products, Inc.	Restrained pipe joining system for plastic pipe
ES2990227T3 (es)	2008-01-17	2024-11-29	Sequenom Inc	Composiciones y procedimientos de análisis de ácido nucleico de secuencia única
US20100119528A1 (en) *	2008-01-17	2010-05-13	Gobinda Sarkar	Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
US20090203531A1 (en) *	2008-02-12	2009-08-13	Nurith Kurn	Method for Archiving and Clonal Expansion
CA2717320A1 (en) *	2008-03-11	2009-09-17	Sequenom, Inc.	Nucleic acid-based tests for prenatal gender determination
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
GB2470672B (en)	2008-03-21	2012-09-12	Nugen Technologies Inc	Methods of RNA amplification in the presence of DNA
DK2285819T3 (da) *	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
US8082730B2 (en) *	2008-05-20	2011-12-27	Caterpillar Inc.	Engine system having particulate reduction device and method
EP2324044A4 (en)	2008-08-04	2012-04-25	Univ Miami	STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS
NZ601660A (en)	2008-08-25	2014-05-30	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8962247B2 (en) *	2008-09-16	2015-02-24	Sequenom, Inc.	Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en)	2008-09-16	2013-07-02	Sequenom, Inc.	Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8604192B2 (en) *	2008-09-24	2013-12-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acids analogs
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
MX2011004097A (es)	2008-10-15	2011-07-28	Isis Pharmaceuticals Inc	Modulacion de la expresion del factor 11.
WO2010048549A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
EP2358398A2 (en)	2008-10-24	2011-08-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CN106955360A (zh)	2008-11-24	2017-07-18	西北大学	多价rna纳米颗粒组合物
RU2620970C2 (ru)	2008-12-04	2017-05-30	КьюРНА,Инк.,	Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
EP2370580B1 (en)	2008-12-04	2019-09-11	CuRNA, Inc.	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CN102361985B (zh)	2008-12-04	2017-06-20	库尔纳公司	通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
AU2009335740B2 (en)	2008-12-17	2016-04-21	Sarepta Therapeutics, Inc.	Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010081049A1 (en) *	2009-01-08	2010-07-15	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
WO2010087994A2 (en)	2009-01-30	2010-08-05	Whitehead Institute For Biomedical Research	Methods for ligation and uses thereof
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
KR101805199B1 (ko)	2009-02-12	2017-12-05	큐알엔에이, 인크.	신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ) 관련된 질환의 치료
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2403946A4 (en)	2009-03-04	2012-11-14		TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
EP2408919B1 (en)	2009-03-16	2017-10-18	CuRNA, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CA2755404C (en)	2009-03-17	2020-03-24	Curna, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US20100297127A1 (en)	2009-04-08	2010-11-25	Ghilardi Nico P	Use of il-27 antagonists to treat lupus
EP3248618A1 (en)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Innate immune suppression enables repeated delivery of long rna molecules
CA2760589C (en)	2009-05-01	2019-08-20	Joseph Collard	Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101722541B1 (ko)	2009-05-06	2017-04-04	큐알엔에이, 인크.	Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CA2762987A1 (en)	2009-05-22	2010-11-25	Joseph Collard	Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
CA2765700C (en)	2009-06-16	2021-01-05	Opko Curna, Llc	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh)	2009-06-26	2016-11-09	库尔纳公司	通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
SI2453923T1 (sl)	2009-07-14	2016-04-29	Mayo Foundation For Medical Education And Research	S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
ES2585360T3 (es)	2009-08-05	2016-10-05	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
EP2462153B1 (en)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
EP2470657B1 (en)	2009-08-25	2019-10-23	CuRNA, Inc.	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
DK2470656T3 (da)	2009-08-27	2015-06-22	Idera Pharmaceuticals Inc	Sammensætning til hæmning af genekspression og anvendelser heraf
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
US8697386B2 (en)	2009-10-22	2014-04-15	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
DK2494075T3 (en)	2009-10-30	2018-07-23	Univ Northwestern	TABLE-MANAGED NANOCONJUGATES
AU2010319314C1 (en)	2009-11-13	2016-09-01	Sarepta Therapeutics, Inc.	Antisense antiviral compound and method for treating influenza viral infection
BR112012012750A2 (pt)	2009-11-30	2020-08-11	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado e método
CA2782366A1 (en)	2009-12-16	2011-07-14	Opko Curna, Llc	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
EP3088532B1 (en)	2009-12-22	2019-10-30	Sequenom, Inc.	Processes and kits for identifying aneuploidy
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
NO2516648T3 (2)	2009-12-23	2018-04-07
US8921334B2 (en)	2009-12-29	2014-12-30	Curna, Inc.	Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko)	2010-01-06	2018-04-30	큐알엔에이, 인크.	췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
KR101854926B1 (ko)	2010-01-11	2018-05-04	큐알엔에이, 인크.	성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
DK2529015T3 (en)	2010-01-25	2018-02-26	Curna Inc	TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
RU2608496C2 (ru)	2010-02-22	2017-01-18	Курна, Инк.	Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
TWI429453B (zh)	2010-02-23	2014-03-11	建南德克公司	抗tat419抗體及其用途
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
EP2545173A2 (en)	2010-03-12	2013-01-16	Sarepta Therapeutics, Inc.	Antisense modulation of nuclear hormone receptors
EP3210611B1 (en)	2010-03-12	2019-08-21	The Brigham and Women's Hospital, Inc.	Methods of treating vascular inflammatory disorders
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
US8980253B2 (en)	2010-04-26	2015-03-17	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en)	2010-04-27	2020-12-08	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
KR101869570B1 (ko)	2010-04-28	2018-06-20	아이오니스 파마수티컬즈, 인코포레이티드	변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
WO2011139853A2 (en)	2010-04-28	2011-11-10	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en)	2010-04-29	2021-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en)	2010-04-29	2020-03-10	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
RS56011B1 (sr)	2010-04-29	2017-09-29	Ionis Pharmaceuticals Inc	Modulacija ekspresije transtiretina
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
CN103096912A (zh)	2010-05-03	2013-05-08	Atyr医药公司	与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8961961B2 (en)	2010-05-03	2015-02-24	a Tyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CN103140233B (zh)	2010-05-03	2017-04-05	Atyr 医药公司	与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
RU2018110642A (ru)	2010-05-03	2019-02-27	Курна, Инк.	Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
JP6008844B2 (ja)	2010-05-04	2016-10-19	エータイアーファーマ，インコーポレイテッド	ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103429739B (zh)	2010-05-12	2018-11-13	哥伦比亚大学纽约管理委员会	制备产生和分泌胰岛素的肠内分泌细胞的方法
ES2816898T3 (es)	2010-05-13	2021-04-06	Sarepta Therapeutics Inc	Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP2568996B1 (en)	2010-05-14	2017-10-04	aTyr Pharma, Inc.	Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096914B (zh)	2010-05-17	2015-08-12	Atyr医药公司	与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
CA2800375C (en)	2010-05-27	2021-03-09	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2580228B1 (en)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2593125B1 (en)	2010-07-12	2017-11-01	aTyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
CN103068982B (zh)	2010-07-14	2017-06-09	库尔纳公司	通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
AU2011293294B2 (en)	2010-08-25	2016-03-24	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
ES2640755T3 (es)	2010-10-06	2017-11-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
ES2677070T3 (es)	2010-10-27	2018-07-27	Curna, Inc.	Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
EP3260540A1 (en)	2010-11-12	2017-12-27	The General Hospital Corporation	Polycomb-associated non-coding rnas
CA3077910A1 (en)	2010-11-17	2012-05-24	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
EP2663323B1 (en)	2011-01-14	2017-08-16	The General Hospital Corporation	Methods targeting mir-128 for regulating cholesterol/lipid metabolism
EP2668199B1 (en)	2011-01-27	2017-09-06	Ramot at Tel Aviv University, Ltd.	Glycogen synthase kinase-3 inhibitors
EP2668200B1 (en)	2011-01-27	2017-03-15	Ramot at Tel-Aviv University Ltd.	Glycogen synthase kinase-3 inhibitors
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
KR101697396B1 (ko)	2011-02-02	2017-01-17	엑스칼리아드 파마슈티컬즈, 인코포레이티드	결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
US8877722B2 (en)	2011-03-25	2014-11-04	Idera Pharmaceuticals, Inc.	Compositions for inhibiting gene expression and uses thereof
WO2012149339A2 (en)	2011-04-29	2012-11-01	Sequenom, Inc.	Quantification of a minority nucleic acid species
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2718439B1 (en)	2011-06-09	2017-08-09	CuRNA, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
HK1200484A1 (zh)	2011-09-14	2015-08-07	Translate Bio Ma, Inc.	多聚寡核苷酸化合物
US9889209B2 (en)	2011-09-14	2018-02-13	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
CA2851280C (en)	2011-10-11	2021-05-18	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
HK1202581A1 (en)	2012-02-13	2015-10-02	Gamida-Cell Ltd.	Mesenchymal stem cells conditioned medium and methods of generating and using the same
HK1206055A1 (en)	2012-03-02	2015-12-31	Sequenom, Inc.	Methods and processes for non-invasive assessment of genetic variations
US20150031750A1 (en)	2012-03-15	2015-01-29	The Scripps Research Institute	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9610362B2 (en)	2012-03-16	2017-04-04	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of DMPK
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
JP2015518485A (ja)	2012-04-20	2015-07-02	アプタミアールセラピューティクスインコーポレイテッド	熱発生のｍｉＲＮＡ調節剤
EP3597741A1 (en)	2012-04-27	2020-01-22	Duke University	Genetic correction of mutated genes
WO2013173652A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
JP2015523854A (ja)	2012-05-16	2015-08-20	ラナセラピューティクスインコーポレイテッド	Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
US10504613B2 (en)	2012-12-20	2019-12-10	Sequenom, Inc.	Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en)	2012-05-21	2018-03-20	Sequenom, Inc.	Methods and compositions for analyzing nucleic acid
JP2015519899A (ja)	2012-05-21	2015-07-16	ザスクリプスリサーチインスティテュート	リボソームポリヌクレオチドおよび関連する発現系
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20140093873A1 (en)	2012-07-13	2014-04-03	Sequenom, Inc.	Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
EP2885312B1 (en)	2012-08-15	2025-09-03	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CN104918639B (zh)	2012-10-22	2018-01-26	萨拜格Rfa公司	用于将治疗剂递送到活细胞和细胞核中的系统
HK1216655A1 (zh)	2013-03-13	2016-11-25	Sequenom, Inc.	用於dna甲基化分析的引物
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
DK2991656T3 (da)	2013-05-01	2020-03-23	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
EP3007704B1 (en)	2013-06-13	2021-01-06	Antisense Therapeutics Ltd	Combination therapy for acromegaly
WO2014207743A2 (en)	2013-06-24	2014-12-31	Ramot At Tel-Aviv University Ltd.	Glycogen synthase kinase-3 inhibitors
KR20160068855A (ko)	2013-10-11	2016-06-15	제넨테크, 인크.	Nsp4 억제제 및 사용 방법
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
EP3099333B8 (en)	2014-01-31	2020-12-30	Temple University of the Commonwealth System of Higher Education	Bag3 as a target for therapy of heart failure
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
US11365447B2 (en)	2014-03-13	2022-06-21	Sequenom, Inc.	Methods and processes for non-invasive assessment of genetic variations
EP3119789B1 (en)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
CN106103717A (zh)	2014-03-19	2016-11-09	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
RS60707B1 (sr)	2014-04-01	2020-09-30	Biogen Ma Inc	Kompozicije za modulaciju ekspresije sod-1
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
SG11201608502TA (en)	2014-05-01	2016-11-29	Ionis Pharmaceuticals Inc	Compositions and methods for modulating complement factor b expression
EP4039807A1 (en)	2014-06-10	2022-08-10	Erasmus University Rotterdam Medical Center	Antisense oligonucleotides useful in treatment of pompe disease
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
EP3160503B1 (en)	2014-06-26	2021-02-17	The Trustees of Columbia University in the City of New York	Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
BR112017004056A2 (pt)	2014-09-12	2017-12-05	Biogen Ma Inc	composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
WO2016049512A1 (en)	2014-09-26	2016-03-31	University Of Massachusetts	Rna-modulating agents
KR20170078843A (ko)	2014-11-21	2017-07-07	노오쓰웨스턴 유니버시티	구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
US10676726B2 (en)	2015-02-09	2020-06-09	Duke University	Compositions and methods for epigenome editing
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
GB201507926D0 (en) *	2015-05-08	2015-06-24	Proqr Therapeutics N V	Improved treatments using oligonucleotides
JP7497953B2 (ja)	2015-06-12	2024-06-11	アレクトルエルエルシー	抗ｃｄ３３抗体及びその使用方法
JP7376977B2 (ja)	2015-06-12	2023-11-09	アレクトルエルエルシー	抗ｃｄ３３抗体及びその使用方法
CA2990852A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CA2991045A1 (en)	2015-06-29	2017-01-05	Caris Science, Inc.	Therapeutic oligonucleotides binding c1q
AU2016298317B2 (en)	2015-07-28	2021-02-18	Caris Science, Inc.	Targeted oligonucleotides
US10072065B2 (en)	2015-08-24	2018-09-11	Mayo Foundation For Medical Education And Research	Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CA2996059A1 (en)	2015-08-28	2017-03-09	Alector Llc	Anti-siglec-7 antibodies and methods of use thereof
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
ES2941968T3 (es)	2015-10-01	2023-05-29	The Whitehead Institute For Biomedical Res	Marcaje de anticuerpos
EP4089175A1 (en)	2015-10-13	2022-11-16	Duke University	Genome engineering with type i crispr systems in eukaryotic cells
CA3003458A1 (en)	2015-10-29	2017-05-04	Alector Llc	Anti-siglec-9 antibodies and methods of use thereof
AU2016349954B2 (en)	2015-11-05	2022-08-25	Antisense Therapeutics Ltd	Mobilizing leukemia cells
AU2016355178B9 (en)	2015-11-19	2019-05-30	Massachusetts Institute Of Technology	Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
EA201891317A3 (ru)	2015-11-30	2019-04-30	Дьюк Юниверсити	Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
CA3007152A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
US20190002887A1 (en)	2015-12-31	2019-01-03	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
US11234996B2 (en)	2016-02-25	2022-02-01	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting SMOC2
AU2017234678A1 (en)	2016-03-16	2018-08-16	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
EP4339288A3 (en)	2016-03-18	2024-06-05	Caris Science, Inc.	Oligonucleotide probes and uses thereof
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US20190127736A1 (en)	2016-04-29	2019-05-02	Aptamir Therapeutics, Inc.	Inhibition of mir-22 mirna by apt-110
CA3025486A1 (en)	2016-05-25	2017-11-30	Caris Science, Inc.	Oligonucleotide probes and uses thereof
EP3471781A4 (en)	2016-06-17	2020-05-06	Ionis Pharmaceuticals, Inc.	MODULATION OF GYS1 EXPRESSION
WO2018013525A1 (en)	2016-07-11	2018-01-18	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
WO2018017754A1 (en)	2016-07-19	2018-01-25	Duke University	Therapeutic applications of cpf1-based genome editing
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
EP3522898A4 (en)	2016-10-06	2020-05-27	Ionis Pharmaceuticals, Inc.	METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
CA3037046A1 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
US11147249B2 (en)	2016-12-08	2021-10-19	Alector Llc	Siglec transgenic mice and methods of use thereof
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
EP3609521A4 (en)	2017-04-14	2021-06-16	University of Massachusetts	TARGETING OF CELL TROPISM RECEPTORS TO INHIBIT INFECTION BY THE CYTOMEGALOVIRUS
CN110536694A (zh)	2017-04-20	2019-12-03	Atyr 医药公司	用于治疗肺部炎症的组合物和方法
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
WO2018213316A1 (en)	2017-05-16	2018-11-22	Alector Llc	Anti-siglec-5 antibodies and methods of use thereof
KR102733407B1 (ko)	2017-08-03	2024-11-21	알렉터 엘엘씨	항-cd33 항체 및 이의 이용 방법
US11197884B2 (en)	2017-08-18	2021-12-14	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
WO2019055460A1 (en)	2017-09-13	2019-03-21	The Children's Medical Center Corporation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US11470827B2 (en)	2017-12-12	2022-10-18	Alector Llc	Transgenic mice expressing human TREM proteins and methods of use thereof
US11459564B2 (en)	2017-12-21	2022-10-04	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
WO2019140102A1 (en)	2018-01-10	2019-07-18	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
BR112020014425A2 (pt)	2018-01-15	2020-12-29	Ionis Pharmaceuticals, Inc.	Moduladores de expressão de dnm2
WO2019144061A1 (en)	2018-01-19	2019-07-25	Duke University	Genome engineering with crispr-cas systems in eukaryotes
EP3759127A4 (en)	2018-03-02	2022-03-30	Ionis Pharmaceuticals, Inc.	COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
WO2019183570A1 (en)	2018-03-22	2019-09-26	Board Of Regents, The University Of Texas System	Soluble interleukin-7 receptor (sil7r) molulating therapy to treat autoimmune diseases and cancer
US11661601B2 (en)	2018-03-22	2023-05-30	Ionis Pharmaceuticals, Inc.	Methods for modulating FMR1 expression
EP4051799A2 (en)	2018-03-30	2022-09-07	Rheinische Friedrich-Wilhelms-Universität Bonn	Aptamers for targeted activaton of t cell-mediated immunity
AU2019247490A1 (en)	2018-04-06	2020-10-22	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
CA3094020A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
SG11202010215TA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn3 expression
US12582702B2 (en)	2018-05-11	2026-03-24	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
MX2020013172A (es)	2018-06-08	2021-03-29	Alector Llc	Anticuerpos anti-siglec-7 y sus metodos de uso.
CA3103429A1 (en)	2018-06-14	2019-12-19	Don W. Cleveland	Compounds and methods for increasing stmn2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
CA3105394A1 (en)	2018-07-02	2020-01-09	Aptamir Therapeutics, Inc.	Targeted delivery of therapeutic agents to human adipocytes
EP3823725A4 (en)	2018-07-17	2023-05-10	Aronora, Inc.	METHODS FOR SAFELY REDUCING THROMBOPOIETIN
BR112021000308A2 (pt)	2018-07-25	2021-04-13	Ionis Pharmaceuticals, Inc.	Compostos e métodos para redução da expressão de atxn2
JP7535495B2 (ja)	2018-07-27	2024-08-16	アレクトルエルエルシー	抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3843845B1 (en)	2018-08-29	2026-03-11	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
MX2021002299A (es)	2018-08-31	2021-04-28	Alector Llc	Anticuerpos de anti-cd33 y metodos para usarlos.
US12097239B2 (en)	2018-09-21	2024-09-24	President And Fellows Of Harvard College	Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
BR112021008967A2 (pt)	2018-11-15	2021-08-17	Ionis Pharmaceuticals, Inc.	moduladores da expressão de irf5
SG11202103794QA (en)	2018-11-21	2021-05-28	Ionis Pharmaceuticals Inc	Compounds and methods for reducing prion expression
SG11202107399WA (en)	2019-01-31	2021-08-30	Ionis Pharmaceuticals Inc	Modulators of yap1 expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
TW202540426A (zh)	2019-02-27	2025-10-16	美商Ionis製藥公司	Malat1表現之調節劑
FI3947684T3 (fi)	2019-03-29	2025-05-27	Ionis Pharmaceuticals Inc	Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi
EP3956450B1 (en)	2019-07-26	2025-08-13	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gfap
EP4013767A4 (en)	2019-08-15	2023-10-25	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds and uses thereof
US12241830B2 (en)	2019-12-06	2025-03-04	Broad Institute, Inc.	Living biosensors
CR20220485A (es)	2020-02-28	2022-11-10	Ionis Pharmaceuticals Inc	Compuestos y métodos para modular smn2
MX2022013707A (es)	2020-05-01	2022-12-07	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular atxn1.
WO2021243271A2 (en)	2020-05-29	2021-12-02	Front Range Biosciences, Inc.	Methods and compositions for pathogen detection in plants
BR112022024206A2 (pt)	2020-06-29	2023-01-03	Ionis Pharmaceuticals Inc	Compostos e métodos para modular plp1
US20230002779A1 (en)	2020-06-29	2023-01-05	Front Range Biosciences, Inc.	Characterization of plant cultivars based on terpene synthase gene profiles
AU2021315992A1 (en)	2020-07-28	2023-02-09	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing app expression
IL300258A (en)	2020-08-07	2023-03-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating SCN2A
EP4136092B1 (en)	2020-11-18	2024-07-31	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating angiotensinogen expression
JP2023554346A (ja)	2020-12-18	2023-12-27	アイオーニスファーマシューティカルズ，インコーポレーテッド	第ｘｉｉ因子を調節するための化合物及び方法
US20240117356A1 (en)	2020-12-31	2024-04-11	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20240023602A (ko)	2021-06-18	2024-02-22	아이오니스 파마수티컬즈, 인코포레이티드	Ifnar1 발현을 감소시키기 위한 화합물 및 방법
US20240376473A1 (en)	2021-09-16	2024-11-14	Qmine Co., Ltd.	Antisense compound for modulating wfdc2 expression
IL318625A (en)	2022-07-29	2025-03-01	Regeneron Pharma	Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
WO2024044352A1 (en)	2022-08-26	2024-02-29	The General Hospital Corporation	Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
JP2025532127A (ja)	2022-09-23	2025-09-29	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍｅｃｐ２発現を低減する化合物及び方法
IL320016A (en)	2022-11-04	2025-06-01	Regeneron Pharma	Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
AU2023379457A1 (en)	2022-11-14	2025-05-15	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2025090427A1 (en)	2023-10-23	2025-05-01	University Of Rochester	Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025184324A1 (en)	2024-02-28	2025-09-04	The General Hospital Corporation	Methods and compositions for prognosis and treatment of cancer therapy-related cardiac dysfunction
WO2025184318A1 (en)	2024-02-28	2025-09-04	The General Hospital Corporation	Methods and compositions for prognosis and treatment of peripartum cardiomyopathy
WO2026080442A2 (en)	2024-10-07	2026-04-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for treating fibrotic and inflammatory diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5149797A (en) *	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
DE4110085A1 (de) *	1991-03-27	1992-10-01	Boehringer Ingelheim Int	2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
WO1994008003A1 (en) *	1991-06-14	1994-04-14	Isis Pharmaceuticals, Inc.	ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
CA2126451A1 (en) *	1991-12-24	1993-07-08	Brett P. Monia	Compositions and methods for modulating .beta.-amyloid
KR940703846A (ko) *	1991-12-24	1994-12-12	비. 린네 파샬	갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
KR940703677A (ko) *	1991-12-31	1994-12-12	토루 페더슨	약물내성 말라리아에 대해 활성인 항기생충 올리고누클레오티드(antipar-asitic oligonucleotides active against drug resistant malaria)
US5681747A (en) *	1992-03-16	1997-10-28	Isis Pharmaceuticals, Inc.	Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5652355A (en) *	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
CA2140542A1 (en) *	1992-07-27	1994-02-03	Abeysingle Padmapriya	Oligonucleotide alkylphosphonothioates
WO1994007367A1 (en) *	1992-09-29	1994-04-14	Apollon, Inc.	Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
JP3160105B2 (ja) *	1992-12-11	2001-04-23	三共株式会社	プシコフラノース及びプシコピラノース誘導体
AU6527094A (en) *	1993-03-31	1994-10-24	Hybridon, Inc.	Modified oligonucleotides having improved anti-influenza activity
CN1123038A (zh) *	1993-05-11	1996-05-22	北卡罗来纳大学查珀尔希尔分校	阻止异常剪接的反义寡核苷酸及其使用方法
JPH09505465A (ja) *	1993-09-28	1997-06-03	ザジェネラルホスピタルコーポレイション	神経増殖を調整し、β／Ａ４アミロイド誘発形態を逆転させる為のアンチセンスオリゴヌクレオチドの使用

1995
- 1995-08-17 US US08/516,454 patent/US5652356A/en not_active Expired - Lifetime
1996
- 1996-08-16 ES ES03010207T patent/ES2315442T3/es not_active Expired - Lifetime
- 1996-08-16 DK DK96930536T patent/DK1019428T3/da active
- 1996-08-16 CA CA2229811A patent/CA2229811C/en not_active Expired - Lifetime
- 1996-08-16 EP EP03010207A patent/EP1340765B1/en not_active Expired - Lifetime
- 1996-08-16 AT AT03010207T patent/ATE411333T1/de not_active IP Right Cessation
- 1996-08-16 DE DE69628864T patent/DE69628864T2/de not_active Expired - Lifetime
- 1996-08-16 AU AU69538/96A patent/AU6953896A/en not_active Abandoned
- 1996-08-16 WO PCT/US1996/013371 patent/WO1997006662A2/en not_active Ceased
- 1996-08-16 ES ES96930536T patent/ES2201198T3/es not_active Expired - Lifetime
- 1996-08-16 JP JP50953597A patent/JP4177455B2/ja not_active Expired - Lifetime
- 1996-08-16 EP EP96930536A patent/EP1019428B1/en not_active Expired - Lifetime
- 1996-08-16 AT AT96930536T patent/ATE243706T1/de not_active IP Right Cessation
- 1996-08-16 DE DE69637718T patent/DE69637718D1/de not_active Expired - Lifetime
- 1996-08-16 PT PT96930536T patent/PT1019428E/pt unknown
1997
- 1997-07-01 US US08/886,860 patent/US5773601A/en not_active Expired - Lifetime
- 1997-07-01 US US08/886,670 patent/US5973136A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1019428T3 (da)	2003-09-22
WO1997006662A2 (en)	1997-02-27
EP1340765B1 (en)	2008-10-15
DE69628864D1 (de)	2003-07-31
ATE243706T1 (de)	2003-07-15
DE69637718D1 (de)	2008-11-27
AU6953896A (en)	1997-03-12
US5973136A (en)	1999-10-26
EP1340765A3 (en)	2006-06-21
ES2201198T3 (es)	2004-03-16
WO1997006662A3 (en)	1997-06-19
JPH11512088A (ja)	1999-10-19
US5773601A (en)	1998-06-30
EP1019428A2 (en)	2000-07-19
ATE411333T1 (de)	2008-10-15
CA2229811A1 (en)	1997-02-27
EP1340765A2 (en)	2003-09-03
US5652356A (en)	1997-07-29
EP1019428B1 (en)	2003-06-25
ES2315442T3 (es)	2009-04-01
CA2229811C (en)	2012-01-03
PT1019428E (pt)	2003-10-31
DE69628864T2 (de)	2004-05-06

Legal Events

Date	Code	Title	Description
2006-08-24	A72	Notification of change in name of applicant	Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060802
2007-10-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071016
2008-02-07	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080116
2008-02-25	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225
2008-03-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080215
2008-03-24	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324
2008-04-10	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080317
2008-04-28	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428
2008-05-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080414
2008-07-17	TRDD	Decision of grant or rejection written
2008-07-29	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080729
2008-07-31	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2008-08-28	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080822
2008-08-29	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110829 Year of fee payment: 3
2008-08-29	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2011-08-11	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110829 Year of fee payment: 3
2011-08-16	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120829 Year of fee payment: 4
2012-08-09	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120829 Year of fee payment: 4
2012-08-14	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130829 Year of fee payment: 5
2013-08-13	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-08-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-08-18	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-08-16	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JP4177455B2 (ja)	2008-11-05	逆キメラおよびハイブリッドオリゴヌクレオチド
US5856462A (en)	1999-01-05	Oligonucleotides having modified CpG dinucleosides
US5968909A (en)	1999-10-19	Method of modulating gene expression with reduced immunostimulatory response
US5585479A (en)	1996-12-17	Antisense oligonucleotides directed against human ELAM-I RNA
CA2153158A1 (en)	1994-07-21	Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US20030036516A1 (en)	2003-02-20	Method for using oligonucleotides having modified cpg dinucleotides
US5969117A (en)	1999-10-19	Modified protein kinase a-specific oligonucleotide
WO1997011171A9 (en)	1997-07-17	Modified protein kinase a-specific oligonucleotides and methods of their use
US6624293B1 (en)	2003-09-23	Modified protein kinase A-specific oligonucleotides and methods of their use
AU646643B2 (en)	1994-03-03	Antisense oligonucleotides to C-ABL proto-oncogene
EP0760666A1 (en)	1997-03-12	Use of oligonucleotide phosphorothioate for depleting complement and for reducing blood pressure
EP1007656B1 (en)	2006-09-13	Modified protein kinase a-specific hybrid oligonucleotide in combination with paclitaxol and methods of their use
WO1998049287A2 (en)	1998-11-05	Antisense oligonucleotides specific for thymidylate synthase
WO2025190276A1 (zh)	2025-09-18	抑制dmpk表达的多核苷酸分子及其用途